Date updated:06-14-2008
The following is a list of companies from a collection of various research reports.

-
CHK
Chesapeake Energy - $24.22
- 0.00%
- $N/A
Strong Buy - Price 58.05 on June 10 by Raymond James Based on our 50% "risking" of the acreage and relatively conservative estimates of flow rates and recoveries, we believe the [newly announced 500,000-net-acre Haynesville Shale, La.] play adds above $25 a share in net asset value, thus we're raising our target from 70 to 85....Conservative estimates on remaining shale acreage (Fayetteville, Marcellus) increases the total company NAV to a price [above] $100/share....Despite vast...holdings and extremely visible growth rate, CHK still trades at a valuation of $4.07 [per thousand cubic feet of natural-gas equivalent] on proven reserves and 6.8 times '09 [earnings before interest, taxes, depreciation and amortization], versus our large-cap universe median of $4.23/mcfe and 6.5 times. Market cap: $29.9 billion.

-
DWA
Dreamworks Animat - $33.05
- -0.72%
- $33.03
Neutral - Price 31.69 on June 10 by Cowen & Co. Kung Fu Panda will likely be DWA's first non-Shrek film to exceed $200 million domestic box office...We expect Panda to perform roughly in-line with Madagascar....We believe DWA shares are likely to trade near current levels through the release of Madagascar: Escape 2 Africa on Nov. 7, which should be the next catalyst for DWA (up or down). We [reiterate] Neutral rating, due to DreamWorks' uneven track record [on] film quality. Market cap: $2.9 billion.

-
IVZ
Invesco Plc New - $23.09
- 0.00%
- $N/A
Buy - Price 26.95 on June 10 by Sandler O'Neill Although May [assets under management] were already about 1% ahead of our $486 billion forecast for the quarter's end, we're leaving our '08 and '09 [earnings-per-share estimates] unchanged at $1.72 and $2.09; [and despite] recent equity-market pullbacks, [reiterate our] 32 target, which represents almost 20% upside potential from current level. Market cap: $11.5 billion.

-
LO
Lorillard - $77.65
- 0.00%
- $N/A
Outperform - Price 72.04 on June 10 by Credit Suisse Following the split-off from Loews, LO [previously traded as Carolina Group] will start trading as an independent company. We believe LO stock will be supported by...elimination of the overhang from the splitoff, addition of LO to the [Standard & Poor's 500 index], LO's more attractive relative fundamentals in a difficult operating environment, and take-out potential...To reflect elimination of CG-specific items, we're updating our fiscal-year 2008 EPS estimate to $5.19 (from $5.14) and our FY09 EPS estimate to $5.69 (from $5.64).

-
PAYX
Paychex - $30.37
- 0.00%
- $N/A
Sector Perform - Price 33.17 on June 10 by RBC Capital Markets We're reducing our growth rates for Paychex due to negative impact of rising unemployment [and] weak U.S. economy['s effect] on small business. Increased customer bankruptcies, declining checks per client and slower new-business [pace may] reduce core payroll growth to below its 8% target. Three-year estimated EPS growth: 7.38%. Target 34 assumes 21 times our forward E-EPS, $1.63 (was $1.61). Market cap: $11.9 billion.

-
TWTI
Third Wave Techno - $0.00
- 0.00%
- $N/A
Outperform - Price 11.15 on June 10 by Baird Securities Hologic announced...a definitive agreement to acquire TWTI in a cash deal worth $11.25/share, [which we see as] positive for TWTI shareholders. Our 12 target is based on target price/sales multiple of 9 times, which we think is in line with historical P/S range of six to 13 times in comparative...specialty diagnostics. We're using a 2009 sales basis for TWTI to reflect its potential [to enter] high-growth markets such as [human papillomavirus] and pharmacogenomics. Market cap: $488 million.

-
VRTX
Vertex Pharmaceut - $39.22
- +1.24%
- $38.60
Market Perform - Price 32.96 on June 10 by Rodman & Renshaw Telaprevir [looks like] the most promising therapy for hepatitis-C in development....With headline risk in next six to nine months from competitors' [advance], we believe VRTX shares will perform in line with biotech indexes. Reiterate our Market Perform. Market cap: $4.6 billion.

-
WNR
Western Refining - $5.42
- -3.73%
- $5.48
Sell - Price 12.11 on June 10 by Soleil Group WNR's debt troubles are add[ing] to difficult year...with the shares having declined about 80% from its July 2007 highs versus a 12% drop in the S&P 500....But with WRF trading at a significant premium to its peers on 2008 and 2009 EV/Ebitda, high regulatory and maintenance capital expenditures...and the likelihood that a debt covenant will be broken at the end of 2Q08, we believe additional downside in the share price remains. Market cap: $827.4 million.
- Top Professional Portfolios
- 1. Navellier & Associ...
- 2. Fidelity Contrafund - ...
- 3. Argus Management
- 4. Charlie Munger
- 5. Calamos Advisors
- show all
- Top Do-It-Yourself Portfolios
- » Joy
- » tsamanuli Portfolio 1
- » Albo's First Portfolio
- » Fundsonly Portfolio 1
- » rk00005
- show all
- Most Viewed Portfolios
- » Warren Buffett
- » George Soros
- » T. Boone Pickens - BP Cap...
- » Carl Icahn
- » Renaissance Technologies
- show all
By Roberto Pedone Posted on Nov. 9, 2009 Financial-Services Bull: Barron’s talks with Anton Schutz, portfolio manager at the Burnham Financial Industries Fund (BURFX)...
By Jonas Elmerraji Posted on Nov. 9, 2009 Last week brought investors a welcome return to gains as the S&P 500 pushed up 3.2% over the course of the last five trading d...
By Roberto Pedone Posted on Nov. 6, 2009 According to Jim Cramer, the bears are tellinginvestors six lies. On Wednesday’s “Mad Money” TV show, Cramer said if you ...
By Roberto Pedone Posted on Nov. 5, 2009 The traders on CNBC’s “Fast Money” told their viewers what they must know after Warren Buffett announced on Tuesday his l...
A. The only one I own : SLX,
too hard pick a winner out all of them
Here are some stocks that moved up on unusual volume on Nov. 2, 2009. more
Here are some of the biggest stocks that made the 52-week high list on Nov. 2, 2009. more
Analyst Upgrades for Nov. 2, 2009. Read more here. more











Comments not available